-
Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.
-
PluriCDMO™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector.
-
PluriCDMO™ includes Pluri’s well-established team as well as a Good Manufacturing Practice (GMP) facility and a state-of-the-art, proprietary bioreactor system enabling 3D cell expansion and supporting the manufacture of stem cells, Induced Pluripotent Stem Cells, Exosomes and Immuno therapeutics.
-
PluriCDMO™ will offer manufacturing support from the preclinical and development stages to late stage clinical and commercial production, including fill and finish and logistics.
-
Andy Lewin, an experienced CDMO executive, will head the new business division.
Core Biogenesis and Nucleus Biologics Announce Strategic Collaboration for Manufacturing and Distribution of Cost-Effective and Sustainable Recombinant Proteins
San Diego, CA, January 10, 2024 – In a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, has signed a manufacturing, distribution, and collaboration agreement with Core Biogenesis, an innovator in the field of recombinant human proteins expressed in plants. This agreement makes Nucleus Biologics the GMP manufacturer for Core Biogenesis’ recombinant proteins and a distributor for the cell and gene therapy market. In addition, Nucleus Biologics, along with their sister company Stoic Bio, will make these recombinant proteins available for their Krakatoa™ pod-based media manufacturing systems. [Read more…]
Exploring Alternative Treatments for Alleviating Pain from Osteoarthritis
As the years pass, our bodies take on many changes. Some we can control and others, like Osteoarthritis (OA), are a little more out of our hands – but that doesn’t mean you have to let it control you! In this article, we will explore the connection between aging and OA, what causes it, how to manage your symptoms effectively so that you can age gracefully with an active lifestyle. So if you’re ready to get proactive about your health as you age and learn how to best manage the effects of osteoarthritis in your life, then stay tuned for some exciting tips. [Read more…]
Ajinomoto Co. to Acquire Gene Therapy CDMO Forge Biologics for an Astounding $620 Million
- Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services
- Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwide
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 63
- Next Page »